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Abstract: Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. 
One of the hallmarks of COPD is an accelerated decline in lung function, as measured by 
  spirometry. Inflammation, oxidative stress and other pathways are hypothesized to be important 
in this deterioration. Because progressive airflow obstruction is associated with considerable 
  morbidity and mortality, a major goal of COPD treatment has been to slow or prevent the 
accelerated decline in lung function. Until recently, the only known effective intervention was 
smoking cessation. However, newly reported large clinical trials have shown that commonly 
used medications may help slow the rate of lung function decline. The effect of these medica-
tions is modest (and thus required such large, expensive trials) and to be of clinical benefit, 
therapy would likely need to start early in the course of disease and be prolonged. Such a 
treatment strategy aimed at preservation of lung function would need to be balanced against 
the side effects and costs of prolonged therapy. A variety of newer classes of medications may 
help target other pathophysiologically important pathways, and could be used in the future to 
prevent lung function decline in COPD.
Keywords: COPD, emphysema, pulmonary function, beta-agonist, anti-inflammatory, 
  pharmacotherapy in COPD
Introduction
Chronic obstructive pulmonary disease (COPD) is a deadly and costly disease, both in the 
United States and around the world. Approximately 20 million Americans are affected, 
and there is likely a similar worldwide prevalence. COPD is increasingly recognized as a 
systemic disease with extra-pulmonary manifestations such as skeletal muscle myopathy, 
osteoporosis, anemia, and depression.1–3 It is also linked with cardiovascular co-morbidities 
and various malignancies.4,5 As a result, COPD is associated with major morbidity and 
mortality. In the United States, COPD is the fourth leading cause of death (behind heart 
disease, cancer and stroke) accounting for more than 119,000 deaths per year; however, 
the number of deaths due to COPD is increasing while most others causes decline.6 
Furthermore, the prevalence and mortality of COPD has been increasing faster over the 
last two decades in women compared to men, so that mortality due to COPD is now equal 
among men and women. Thus, COPD is projected to overtake stroke as the third most 
common cause of death in the US by 2020. The estimated direct cost of COPD in the US 
is substantial, and a portion of this money is spent toward medications designed not only 
to alleviate symptoms, but also ideally to slow disease progression and reduce mortality. 
By 2012, COPD drug costs are expected to reach almost 6 billion dollars per year in 
the US, Japan, and part of Western Europe alone.7 This estimate excludes many large International Journal of COPD 2010:5 154
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and populous areas, such as India and China, where COPD is 
becoming an increasingly recognized and prevalent condition, 
both due to smoking and other sources of air pollution.8,9
While greater emphasis is now placed on extra-pulmonary 
disease, the definition of COPD still rests upon airflow 
obstruction. Airflow obstruction, usually measured using 
spirometry, is a useful marker of disease since testing is 
reasonably reproducible and widely available. The Global 
Initiative for Chronic Obstructive Lung disease (GOLD) 
has proposed spirometric criteria for diagnosis and severity 
assessment of COPD using the forced expiratory volume 
in one second (FEV1) and the ratio of the FEV1 over the 
forced vital capacity (FVC) after bronchodilator.10 When 
incorporated with other clinical information, spirometry can 
also be used to predict survival in COPD.11 Progression of 
airflow obstruction, another hallmark of COPD, can also be 
determined by serial spirometry measurements over time. 
Sustained improvements in spirometry, or at least a reduction 
in the rate of FEV1 decline, should reflect reduced morbidity 
and mortality.
Until recently, the only known intervention to slow 
disease progression was cigarette smoking cessation.12,13 
However, greater understanding of disease pathogenesis has 
provided new targets for intervention. Furthermore, large 
clinical trials have recently been reported in the literature 
to help assess whether commonly used medications slow 
disease progression. This review will focus on COPD 
  pathogenesis, review recent clinical trial results, and highlight 
other potential therapeutic options.
Normal lung function, aging,  
and smoking
Lung function has traditionally been measured using 
  pulmonary function tests, particularly spirometry. However, 
spirometry is actually a measurement of a number of 
physical and mechanical properties of the respiratory 
  system, including resistance of the airways, elasticity of the 
  respiratory system, and contractile forces of the respiratory 
muscles. True lung function may also require assessment of 
arterial oxygen or carbon dioxide tension, but spirometry 
has the advantages of being non-invasive, standardized, and 
reproducible. Normative data are also available, allowing 
appropriate matching for differences in sex, height, race 
and age. Thus, pulmonary function tests are frequently 
used for diagnosis, assessment of disease severity, disease 
  progression, response to treatment, and for prognosis in a 
variety of respiratory disorders.
Consideration of age is necessary given the myriad changes 
that occur in the respiratory system even with normal aging. 
With aging, there are changes not only in lung parenchyma 
but also in chest wall shape and in muscle forces – all of 
which affect spirometry. While the exact shape and details of 
the curve describing lung function (as assessed by FEV1) by 
age has yet to be determined, the general shape is shown in 
Figure 1. As might be expected, FEV1 rapidly increases during 
childhood and adolescence, before reaching a plateau in early 
adulthood.14,15 Interestingly, the peak of lung function appears 
to occur after maximum height has been achieved, so that the 
improvements in spirometry are not just due to increased lung 
size (and thus airway caliber). Lung function remains stable 
at this plateau (with men having a higher plateau value than 
women) until approximately age 25 to 30 years, after which 
FEV1 slowly declines. Although there is some controversy as 
to whether the decline in FEV1 is linear with age or acceler-
ates with aging,16 some of the most robust data suggest that 
lung function decreases approximately 20 mL per year during 
middle age, and then decreases more rapidly by about 38 mL 
per year after age 65.17,18
Regardless of the exact rate of decline in FEV1 with age, 
the decline is likely due to a combination of age-related 
changes of the parenchyma, the chest wall, and the respi-
ratory muscles, which may be difficult to separate using 
spirometry alone. The chest wall may change with aging 
due to reduced height of thoracic vertebrae, or stiffening 
or calcification of the costal joints of the rib cage. Direct 
measurements have confirmed decreased compliance of the 
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Figure 1 Normal changes in FEV1 (solid line) and FVC (dashed line) for men (M) 
and women (F). Reproduced with permission from Janssens JP, Pache JC, Nicod LP. 
Physiological changes in respiratory function associated with ageing. Eur Respir J. 
1999;13(1):197–205.14 Copyright © 1999 European Respiratory Journals Ltd.International Journal of COPD 2010:5 155
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chest wall with aging.19,20 Respiratory muscle function also 
changes with age. Studies of diaphragm strength have shown 
a 13% to 25% drop in the maximal inspiratory force generated 
with aging.21,22 In general, skeletal muscle function, which 
predicts maximal inspiratory and expiratory pressure (MIP 
and MEP), also decreases with age.23,24 Taken together, these 
changes may limit the maximal inspiratory and expiratory 
effort that contribute to FEV1. Perhaps most important in 
explaining the age-related decline are changes in the lung 
parenchyma. Pathological studies have shown that beyond 
age 50 years, elastic fibers at the level of the respiratory 
bronchiole and alveolus degenerate, or rupture and appear 
coiled – although the total number of alveolar connections 
remains unchanged (in contrast to emphysema induced 
by cigarette smoking).25,26 The abnormal and presumably 
weakened connections lead to uniform airspace dilatation, 
a condition that Verbeken and colleagues called “senile 
emphysema.” The functional result of these parenchymal 
lung changes are a decrease in the elastic recoil pressure of 
the lung and a weakening of the supporting structures of the 
small airways, which more easily close, even during tidal 
breathing.27–29 All of these changes contribute to the gradual 
decline in FEV1 with increasing age.
The changes in lung parenchyma (decreased elastic 
recoil), chest wall (increased stiffness), and the respiratory 
muscles (decreased force generation) explain the observed 
changes in lung volume with aging. Total lung capacity 
remains relatively preserved since the increased distensibility 
of the lung is offset by the stiffer chest wall. Residual volume 
(RV) and functional residual capacity (FRC) both increase, 
but expiratory reserve volume (ERV) decreases.30,31
Changes in lung function with  
smoking and COPD
Smoking impacts all phases of lung development and 
growth, and can limit the maximal lung function attained,32,33 
shorten the duration of the plateau phase prior to the decline 
with aging,34 and accelerate the decline in lung function.13 
Although the precise numbers may vary slightly in other 
studies,35,36 the findings of Fletcher and Peto encapsulate the 
known consequences of smoking on lung function decline 
(see Figure 2).13 First, smokers show an accelerated rate of 
decline in FEV1 compared to those who have never smoked; 
an average loss of approximately 50 mL per year. Of note, 
while this rate may be approximately double the normal 
rate of decline, this small absolute change per year could be 
difficult to detect in short trials. Second, on average there is 
a dose-dependent loss in lung function: in general, greater 
amounts of smoking lead to greater declines in FEV1. Third, 
there is variable susceptibility to the effects of smoking. 
That is, for a given amount of smoking, there is a variable 
rate of decline in lung function among different subjects, 
  presumably reflecting genetic37 or other environmental 
  factors, although the rate of decline appears to be similar 
between men and women.35,38 Studies of lung function 
decline must be interpreted in terms of this “Horse Racing 
Effect” – the observation that in a race, the faster horse will 
be out in front in the middle of the race. In the context of 
  smoking and lung function decline, subjects with evident 
lung function loss and clinical COPD are likely those with 
the fastest loss of lung function. Conversely, most smokers 
will not develop clinically significant COPD.39 Finally, the 
rate of lung function decline will slow, and may return to 
normal with smoking cessation. Whether the diagnosis of 
COPD by itself (ie, after smoking cessation) causes more 
rapid decline in lung function is unknown, and is difficult 
to decipher from the effects of smoking unless there is 
adequate follow-up time, typically several years.40 Airway 
  inflammation continues to persist for many years after smok-
ing cessation, and improvements in hospitalization are not 
generally seen until years after smoking cessation.12,41 There-
fore definitive data regarding COPD alone without smoking 
are difficult to obtain.
Pathogenesis and pathology  
of COPD
Knowledge about the pathogenesis of COPD will be helpful 
in understanding the causes of and ultimately treating the 
accelerated lung function decline. COPD is now recognized as 
a systemic inflammatory disease, not just affecting the airways 
and lung parenchyma, but many other organs as well. The 
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Figure 2 The decline in lung function with age, smoking, and smoking cessation. 
Note that the decline in lung function among “susceptible” smokers will be variable. 
Reproduced with permission from Fletcher C, Peto R. The natural history of chronic 
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GOLD definition emphasizes that the disease has systemic 
effects due to abnormal inflammation, defining COPD as:
“a preventable and treatable disease with some signifi-
cant extra-pulmonary effects that may contribute to the 
  severity in individual patients. Its pulmonary component 
is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and 
associated with an abnormal inflammatory response of the 
lung to noxious particles or gases.10
Two patterns of airflow obstruction are commonly 
described, which can overlap in individual patients. 
An obstructive bronchiolitis can result from structural changes 
and narrowing of small airways. Parenchymal destruction 
leads to emphysema, with loss of supporting structures 
around the airways. The loss of elastic recoil promotes airway 
  collapse during exhalation.
Inflammation, oxidation,  
and premature aging
The abnormal inflammatory response that causes these 
  patterns of injury has yet to be fully characterized, and there 
are likely multiple pathways that lead to impaired lung 
  function. Three major proposed mechanisms are: activation of 
elastolytic proteases, chronic oxidative stress, and accelerated 
aging.42–44 Cigarette smoking provides the initial stimulus 
which recruits cells into the lung parenchyma. Circulating 
monocytes become macrophages in the lung and subsequently 
recruit additional macrophages, neutrophils, and activated 
T-lymphocytes. The level of inflammation in COPD lungs is 
greater than that seen in the lungs of smokers without COPD, 
and the number of neutrophils in sputum is predictive of lung 
  function decline.45 Unlike asthma, the inflammation with 
COPD is generally resistant to the effects of corticosteroids, 
and these pathological changes are progressive. Once activated, 
the recruited cells release enzymes such as neutrophil elas-
tase and matrix metalloproteinase-9 (MMP-9) which destroy 
normal lung tissue. One of the hallmarks of COPD is this 
imbalance between proteases, which are part of the normal 
host defense to bacteria or foreign bodies, and inactivating 
anti-proteases;46 the subset of patients with genetic deficits in 
alpha-1 antitrypsin, a protease inhibitor, are a good example 
of this principle. One other clinical observation that suggests 
  protease/anti-protease imbalance is the loss of skin elasticity 
and wrinkling that also occurs in and correlates with severity 
of emphysema; this also illustrates the extra-pulmonary effects 
of COPD, although such changes could also be the direct result 
of smoking.47 Oxidative stress may also play a role, either as 
a result of oxidants present in cigarette smoke or the genera-
tion and release of reactive oxygen species from leukocytes. 
Oxidative stress can increase activity of proteases, and lead to 
inactivation of anti-proteases. Finally, the changes seen with 
COPD may be an accelerated version of “senile emphysema.” 
As described above, some of the same pathological changes 
seen with COPD also occur in elderly subjects, such as loss 
of elastic tissue and distal airspace enlargement. Several in 
vitro and animal studies support this hypothesis. For example, 
  fibroblasts from those with emphysema have reduced prolif-
erative capacity compared to control smokers,48 which may be 
related to telomere length. Telomere shortening is accelerated 
by oxidative stress and chronic inflammation. Additionally, the 
anti-aging molecule sirtuin SIRT1 is also reduced in murine 
COPD lungs. These and other changes suggest COPD could 
be a disease of premature aging.49
The inflammation that begins in the lung causes increased 
levels of a number of cytokines, chemokines and acute 
phase reactants. Whether these findings reflect “spill-over” 
of pulmonary inflammation, or a separate activation of a 
generalized inflammatory response, is unknown.3 Those 
with COPD have higher circulating levels of cytokines 
and acute phase reactants than those who smoke but do 
not have COPD. Interleukin-6, tumor necrosis factor alpha 
(TNF-α), interleukin-8, and ghrelin are all elevated in 
COPD, as are C-reactive protein and fibrinogen.3 Although 
the effects of these substances are wide ranging, they prob-
ably modulate some of the systemic effects of COPD. For 
example, circulating IL-6 has been associated with skel-
etal muscle atrophy, and TNF-α with muscle atrophy and 
cachexia. These systemic effects could also contribute to 
decrements in spirometry. Thus, all of the pathways men-
tioned above represent potential targets for therapy.
Exacerbations
Exacerbations of COPD also appear to play a role in lung 
function decline. Although the definition is imprecise 
(and sometimes controversial), exacerbations are usually 
defined clinically by worsening symptoms, and are often 
associated with worsening pulmonary function and 
increased local and systemic inflammation.50 Those with 
frequent exacerbations appear to have more rapid decline 
in lung function and increased mortality (see Figure 3).51–53 
Airway infection due to a variety of bacterial and/or viral 
pathogens is the most likely cause of exacerbations.54,55 
Environmental exposures such as air pollution may also 
play a role, however, in up to one third of cases, no clear 
precipitant for the exacerbation can be identified.10 Because International Journal of COPD 2010:5 157
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the same bacteria can be recovered from the lungs of 
COPD patients both before and during an exacerbation, 
bacterial infection was often dismissed as a cause for 
exacerbation. However, Sethi and colleagues found that 
exacerbations were associated with changes in the specific 
bacterial strain, suggesting that exacerbations can follow 
the acquisition of new pathological strains. Pathogens may 
more easily cause infection in the COPD lung, in which 
several normal defense mechanisms of innate immunity 
are impaired. For example, mucociliary function, alveolar 
macrophage phagocytosis and toll-like receptor expression 
are all impaired in COPD.56
A rational approach to slow lung  
function decline
Based on our current understanding of COPD pathogenesis 
outlined above, there are several targets for intervention. 
These include excessive inflammation, proteolysis, oxidative 
stress, and bacterial and viral infections that may trigger 
exacerbations.
Commonly used COPD 
medications
Bronchodilators
There are two commonly used classes of bronchodilators: 
beta-agonists  and  anti-cholinergics.  Beta-agonists 
  stimulate β-2 adrenergic receptors, increase levels of cyclic 
AMP, and thereby inhibit bronchoconstriction. Inhaled 
forms are preferred because of rapid onset of action and 
favorable side effect profile compared to the oral form. 
Short-acting inhaled beta-agonists, such as albuterol, 
  salbutamol and levalbuterol, have a rapid onset of action 
(within minutes) and a duration of action on the order of 4 to 
6 hours. Long-acting compounds such as salmeterol (onset 
of action up to one hour) and formoterol (onset of action 
within minutes) have a duration of action of approximately 
12 hours without demonstrable tachyphylaxis with 
  regular use.57 Anticholinergics block muscarinic receptors 
(M1, M2, and M3), blocking the action of acetylcholine on 
the airway smooth muscle, which leads to airway smooth 
muscle relaxation. Short-acting anticholinergic preparations 
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  (ipratropium, oxytropium) can have effects lasting up to 
8 hours following administration, while the long-acting 
  preparation (tiotropium) has effects that last more than 
24 hours. Inhaled anticholinergic compounds have very 
limited systemic absorption.
By their effects on smooth muscle, bronchodilators can 
acutely improve lung function, hyperinflation, dyspnea, 
exercise tolerance and lessen the degree of nocturnal 
  hypoxemia.58,59 Bronchodilator medications may also have 
other clinically relevant effects. For example, beta-agonists 
have effects on multiple components of the respiratory 
  system, including: decreased airway smooth muscle 
  proliferation; decreased neutrophil number, activity and 
  function; and increased ciliary beat frequency.60 Some 
or all of these changes could help counteract excessive 
  inflammation, restore innate immunity, or prevent airway 
remodeling. Similarly, the anti-cholinergic tiotropium 
has been shown to decrease respiratory syncytial virus 
replication (RSV) in an in vitro model, and decrease lung 
  fibroblast collagen synthesis.61,62 Thus, these commonly 
used bronchodilators may affect the progression of COPD 
through pathways unrelated to their direct effects on 
  bronchomotor tone.
Corticosteroids
Inhaled corticosteroids are frequently used in severe COPD 
to interrupt inflammatory pathways, although the effect on 
disease is less notable than the use of these medications 
in asthma. At least in moderate to severe COPD, inhaled 
  corticosteroids can decrease the number of exacerbations 
and improve quality of life.63 Unfortunately, several small 
to moderate sized trials using inhaled corticosteroids failed 
to show a consistent effect of these medications on the 
rate of decline in FEV1.63–66 For example, the Lung Health 
Research Study Group randomized more than 1100 sub-
jects with all stages of COPD to the inhaled corticosteroid 
  triamcinolone for 40 months: no difference was seen in the 
rate of lung function decline, the study’s primary outcome.64 
In the ISOLDE trial, 750 patients were randomized to 
inhaled fluticasone vs placebo for three years. The annual 
rate of decline in FEV1 was 50 mL/year in the fluticasone 
group and 59 mL/year in the placebo group, although the 
  difference did not reach statistical significance (P = 0.16).63 
A third contemporary trial by Pauwels and colleagues 
randomized over 1200 patients to budesonide or placebo 
for 3 years, and again, the rate of decline was not statisti-
cally significantly different (P = 0.39) between budesonide 
(−57 mL/year) vs placebo (−69 mL/year). A subgroup 
analysis suggested that the therapy was more effective in 
those who had less cigarette pack-year exposure. These 
studies and others have been combined via meta-analyses 
which reached conflicting conclusions about the efficacy of 
inhaled corticosteroids in ameliorating the decline in lung 
function.67,68 In the positive meta-analysis by Sutherland 
and colleagues, corticosteroids were found to reduce the 
rate of FEV1 decline by 7.7 mL per year compared to pla-
cebo. These moderate size trials illustrate the difficulty in 
detecting the difference in the rate of lung function decline 
between those patients with COPD not on treatment (with 
a reported FEV1 decline of 50 mL per year) and those 
patients with COPD on treatment (expected FEV1 decline 
somewhere between 25 and 50 mL per year). Such small 
differences in lung function decline per year make it dif-
ficult to discern whether treatment with inhaled cortico-
steroids truly does alter lung function decline. Trials with 
both longer periods of active treatment and follow-up will 
be required to better answer this question. In aggregate, the 
existing data support a relatively small effect of inhaled 
steroids on FEV1 decline in COPD.
TORCH and UPLIFT
Two recent very large trials have examined the impact of 
these commonly used medications on the decline in FEV1. 
These trials are fundamentally different from prior work 
due to their large sample size and extended follow-up. The 
first results reported were from the Toward a Revolution in 
COPD Health (TORCH) study.69 This was a multi-center, 
  randomized, double-blind trial comparing treatment in 
  moderate to severe COPD with placebo, salmeterol, 
  fluticasone, or the combination of salmeterol and fluticasone. 
All cause mortality was the primary endpoint, although 
  spirometry and rate of lung function decline was also 
assessed. Over 6000 patients were randomized, with about 
60% of subjects completing the 3-year trial. Overall, the 
combination therapy tended (P = 0.052) to improve absolute 
all-cause mortality by about 2.5%.
A post-hoc analysis, done before treatment unblinding, 
was performed to assess the rate of decline in FEV1 
(see Figure 4).38 In this group of former smokers, the change 
in post-bronchodilator FEV1 was 55 mL per year – similar 
to prior reported values. Treatment with either fluticasone 
or salmeterol was associated with a decline in FEV1 of only 
42 mL per year; and the combination of drugs was 39 mL 
per year (not statistically significantly different from the 
  individual drug components). There are some legitimate 
critiques of the trial. Specifically, dropouts were not randomly International Journal of COPD 2010:5 159
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distributed amongst the different treatment arms, introducing 
potential bias, with significantly more dropout in the placebo 
arm (18% vs 9% in the combination therapy arm). Although 
it could be assumed that those who dropped out had a faster 
rate of lung function decline, Suissa has convincingly shown 
how this assumption could be false, since the data could be 
skewed by the phenomenon of regression to the mean.70,71 
Nevertheless the TORCH trial provides the first evidence 
that treatment of COPD can slow the accelerated decline 
in FEV1. Although there was a significant decrease in the 
number of exacerbations, even in patients who had no exac-
erbations during the trial there was a similar difference in the 
rate of decline between those on placebo (56 mL per year) 
and those with some form of active treatment (27 to 31 mL 
per year). Since there was improvement in both the salmeterol 
and fluticasone groups, but little added improvement in 
the combination group it suggests that there are multiple 
potential mechanisms for improvement in lung function. 
Further studies are needed to elucidate whether there may be 
a limit or ceiling effect on the total amount of improvement 
possible.
The second very large COPD treatment trial was the 
Understanding Potential Long-Term Impacts on Function 
with Tiotropium (UPLIFT) trial.72 This was also a large, 
multi-center, randomized, placebo-controlled trial in 
  moderate to severe COPD patients. Tiotropium was compared 
to placebo with the primary outcome rate of decline in FEV1. 
Importantly, patients were allowed to continue respiratory 
medications other than an inhaled anti-cholinergic, and the 
majority of patients were on a long-acting beta-agonist and/or 
an inhaled corticosteroid. Again, about 6000 patients were 
recruited, with 60% completing 45 months of follow-up. The 
addition of tiotropium did not slow the rate of FEV1 decline 
compared to placebo. In this trial, the rate of decline was 
only 38 mL per year in the treatment arm, and 40 mL per 
year in the placebo arm, only slightly greater than expected 
due to normal aging. Possible explanations of these data are 
the relatively low rate of smoking (as compared to other 
studies), which may have a much greater effect than any 
medication on the rate of lung function decline, and the high 
rate of concurrent use of other kinds of COPD medications. 
In support of this latter hypothesis, there was a difference 
in the rate of decline in post-bronchodilator FEV1 between 
tiotropium and placebo in those subjects not on either an 
inhaled corticosteroid or long-acting beta-agonist (40 ± 3 mL 
per year in the tiotropium group vs 47 ± 3 mL per year in the 
placebo group, P = 0.046). Subgroup analysis of this cohort 
also suggested that the use of tiotropium was also associated 
with a slower rate of decline in the group of patients with 
more mild disease [GOLD stage II (50%  FEV1  80% 
predicted, and FEV1/FVC  70%)].73
Although both TORCH and UPLIFT suggest that 
pharmacotherapy can modestly slow the rate of lung 
function decline, the different types of medications studied 
in each trial presumably work through different pathways. 
Indirect evidence for this comes from the INSPIRE trial, 
which compared the rate of exacerbations in severe COPD 
using combination salmeterol/fluticasone or tiotropium.74 
Although the drugs were equally efficacious at preventing 
exacerbations, when an exacerbation did occur, antibiotics 
were used more frequently in the salmeterol/fluticasone arm 
and steroids more often in the tiotropium arm, suggesting 
that the exacerbations were qualitatively different depending 
on the treatment arm. In clinical practice, all three types of 
medications are often combined, and probably offer addi-
tional benefits in terms of acute changes in FEV1, symptom 
scores and quality of life, but as of yet there are minimal 
long term data to assess the impact of this combination 
therapy on the rate of FEV1 decline since such trials have 
typically only run for 12 months or less.75,76
To summarize: commonly used medications appear to 
modestly slow the accelerated decline in lung function in 
COPD. Inhaled corticosteroids have an anti-inflammatory 
effect, which presumably explains their benefit. In contrast, 
the mechanism by which bronchodilators slow lung function 
decline is unknown. When combined, the effects of different 
classes of medications could be additive. Given the small 
absolute amount of lung function benefit, any clinically 
meaningful preservation of lung function would likely 
require years of daily medication use (as well as very long 
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clinical trials to detect), probably in patients with less severe 
COPD. The lung function preservation benefits would need 
to be weighed against the adverse effects and the costs of 
these medications. While beyond the scope of this review, 
several reported side effects might be important. The inhaled 
corticosteroids have been implicated in greater rates of 
osteoporosis in some,64 but not all,77 trials. In the TORCH 
trial (and some other trials of inhaled corticosteroids78), 
there was a higher rate of pneumonia in the treatment arms 
receiving high-dose fluticasone. For tiotropium specifically, 
there is wide disparity with regard to its reported effects on 
cardiovascular mortality.79
Other COPD medications
Besides the commonly used medications above, other 
pharmacotherapies have been tried based on pathways that 
might be important in COPD pathogenesis and lung func-
tion decline. Most of the work to date is preliminary or of 
limited applicability, but has been interesting and hypothesis 
generating.
Anti-oxidants
Oxidative stress is thought to play a role in COPD patho-
genesis. A number of trials sought to investigate the role 
of antioxidant therapy on exacerbations and lung function 
decline.80 The recently completed BRONCUS trial was 
a 3-year, randomized, placebo controlled trial of 600 mg 
N-acetylcysteine and its effect on exacerbations and the 
rate of decline in FEV1.81 The trial was negative for both 
endpoints, although subgroup analysis suggested that the 
therapy might reduce exacerbations in those not taking 
inhaled corticosteroids (perhaps similar to UPLIFT?). 
Another anti-oxidant, carbocisteine, was recently reported 
in the PEACE trial to decrease exacerbations during 1 year 
of active treatment compared to placebo.82 Carbocisteine 
also has mucolytic and anti-inflammatory properties, so the 
exact mechanism of any benefit is unknown. Nevertheless, 
anti-oxidant therapy is an area of active research for COPD 
treatment and exacerbation prevention.83
Antibiotics
Given the role of exacerbations in COPD pathogenesis, 
morbidity and mortality, many researchers have used 
  antibiotic therapy to prevent exacerbations. As well 
  summarized by Kunisaki and Niewoehner, there is a long 
history of antibiotic use in COPD, but this was mostly 
  abandoned after relatively disappointing trials in the 1950s 
and 1960s.84 Recently, Seemungal and colleagues revived 
the idea in a year-long, randomized, placebo-controlled 
trial of erythromycin.85 In this study, treatment with the 
antibiotic significantly reduced exacerbations in moderate 
to severe COPD. Although macrolides may have other 
anti-inflammatory properties86 there was no evidence of 
an anti-inflammatory effect; that is, the benefits seemed 
to accrue only due to the antimicrobial properties of the 
drug. No difference in lung function decline was seen in 
this (relatively short) 12-month trial. While such a strategy 
focuses on preventing exacerbations, even prompt reporting 
of exacerbations and rapid treatment with antibiotics could 
also influence lung function decline, as well as other COPD 
outcomes.87
Alpha-1-antitrypsin augmentation therapy
Alpha-1-antitrypsin (AAT) deficiency provides a unique 
model of COPD, due to the loss of a protease inhibitor 
in affected individuals. The protease/anti-protease 
  imbalance can be restored by intravenous augmentation 
of AAT. Several non-randomized studies have shown that 
  progression of disease can be slowed by therapy, though 
the effect may be modest and may not be evident for many 
years.88–90 While this specific therapy is not applicable to 
most with COPD,91 these results suggest that anti-protease 
therapy in general could have a role in slowing the decline 
in lung function.
Other anti-inflammatory therapies
Non-steroidal anti-inflammatory therapies have also 
been investigated. Among the most intriguing are the 
results from non-randomized trials looking at statin use 
in COPD. Statins, 3-hydroxy 3-methylglutaryl coenzyme 
A reductase inhibitors, are used extensively to prevent 
cardiovascular disease. In addition to their lipid lowering 
effects, it is clear that they also have anti-inflammatory 
properties.92 Observational trials have suggested that 
statins reduce mortality in COPD, a finding that may not be 
surprising given the risk of cardiovascular disease in this 
  population.93 However, statins have also been reported to 
reduce exacerbations, and in one retrospective observational 
trial statin use was associated with a markedly reduced 
decline in FEV1.94 Because patients who use statins may be 
  fundamentally different from those who do not,95 particularly 
for other medication use and habits, such results will need 
to be supported by randomized trials.
Phosphodiesterases (PDEs) are a family of enzymes that 
inactivate intracellular messengers cyclic AMP and cyclic 
GMP, which play important roles in the activity of many International Journal of COPD 2010:5 161
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  different cell types. PDE-4 has been of interest in COPD since 
this specific enzyme is found in immune and inflammatory 
cells as well as airway smooth muscle cells. PDE-4 inhibition 
can decrease airway inflammation in COPD, as assessed by 
sputum neutrophil and eosinophil counts.96 In addition, one 
small trial showed that tissue inflammation was reduced with 
PDE-4 inhibition, which may suggest a role for these drugs in 
preventing airway and parenchyma remodeling in COPD.97 
Recent trials have shown that in select populations of COPD 
patients, the PDE-4 inhibitor roflumilast can improve lung 
function and reduce exacerbations when administered for 
12 months.98,99 What role, if any, this class of medications 
has in prevention of long-term lung function decline has not 
yet been determined.
Other anti-inflammatory medications have been used, 
such as anti-TNF-α agents. Although a large trial was 
  negative,100 other pathways will no doubt be targeted in the 
future, and perhaps in earlier stages of disease.101
Patient education and patient–physician 
partnership
Although only recently a focus of rigorous investigation, 
patient education and partnership programs between 
patients and healthcare providers are likely to be important 
in COPD management and treatment.102,103 All medications 
require proper administration and dosing to achieve the 
desired effect. Similarly, early intervention in the course 
of an exacerbation may be crucial. Thus, education efforts 
should focus on several important areas including instruction 
on proper use of inhaled medications (particularly those 
  supplied via unique delivery systems), early recognition of 
exacerbations, and avoidance of known precipitants. Patient 
guides are available from several sources, including www.
goldcopd.org and www.internationalcopd.org. At each visit, 
proper compliance with maintenance medications should 
be emphasized. Practitioners should strive for a partnership 
with their patients (and ensure that the necessary systems 
are in place) that would allow for rapid notification and 
treatment of exacerbations. Although not within the realm 
of pharmacotherapy, we welcome further research efforts 
assessing these types of interventions on the rate of lung 
function decline.
Summary
COPD is an inflammatory disease associated with accel-
erated lung function decline. Data from trials with large 
numbers of participants and multi-year follow-up suggest 
that commonly used pharmacotherapy can modestly improve 
the decline in lung function in COPD. Given that the ben-
efit is small, it may be beneficial to start treatment early in 
the course of disease to preserve lung function over time. 
However, such a lung preservation strategy would need 
to be balanced against the potential side effects and costs 
associated with prolonged therapy. Alternatively, other more 
targeted therapies currently under investigation may offer 
greater benefit in the future.
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